secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2026-08-04T20:04:05+00:00
Accession:  0001193125-26-332748
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q2 revenue up 30% to $22.4M; clinical test volume surges 199% YoY
----------------------------------------------------------------------------

- Clinical test volume of 10,384, up 199% YoY and 33% sequentially; clinical revenue $2.6M (+442% YoY).
- Total revenue $22.4M (+30% YoY); pharma testing & other revenue $16.8M (+51%); VA MVP revenue $3.0M (-9%).
- Cash and investments $212.7M; secured Medicare coverage for NeXT Personal IO monitoring and neoadjuvant breast cancer.
- VICTORI study: NeXT Personal detected 100% of relapses; TRACERx data highlights sub-10 ppm sensitivity in lung cancer.
- Due to pending merger with Tempus AI, company will no longer provide financial guidance or hold earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526332748/0001193125-26-332748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312526332748/psnl-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer